Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Inclusion Criteria: 1. Diagnosis of TGCT according to medical records 2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment 3. Has provided informed consent and medical records release Exclusion Criteria: 1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib 2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment 3. Participant is active in an interventional clinical trial of vimseltinib